Neffy Nasal Spray: A New Era for Epinephrine Delivery by ARS Pharmaceuticals Copy

ARS Pharmaceuticals has launched Neffy, a nasal spray that stands as the first needle-free method of epinephrine delivery. This new product holds the potential to revolutionize emergency treatment for asthma and severe allergies, particularly benefiting those with needle phobia.

The epinephrine market has traditionally been dominated by injectable solutions like EpiPen, often criticized for its high prices and limited access. Before the rise of generic options, EpiPens cost over $600 for a two-pack, sparking public outcry. Neffy enters this market as a more convenient alternative, priced at $710 for a two-pack. Despite being higher than some injectors, Neffy’s ease of use and needle-free design offer significant advantages for many patients.

ARS Pharmaceuticals is making strides to enhance Neffy’s accessibility through various programs, including the neffyConnect program in partnership with BlinkRx. This initiative allows eligible insured patients to obtain Neffy at a reduced cost of $25. Uninsured patients can purchase at a cash price of $199, with additional financial assistance available for those who qualify.

With its recent approval by the European Medicines Agency and upcoming FDA expansion plans for pediatric use, Neffy is poised to make a global impact. While overcoming skepticism from healthcare providers remains a challenge, Neffy’s potential to offer a reliable and user-friendly alternative to injectables could redefine epinephrine delivery, particularly for vulnerable groups like children and asthma patients.